Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06231277
Other study ID # BH002-?-101
Secondary ID CTR20220209
Status Completed
Phase Phase 1
First received
Last updated
Start date April 26, 2022
Est. completion date March 31, 2023

Study information

Verified date January 2024
Source Zhuhai Beihai Biotech Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to about in Patients With Advanced Solid Tumors. The main question[s] it aims to answer are: - question 1:Evaluating the tolerability of BH002 injection in Chinese patients with advanced solid tumors - question 2:Obtain the pharmacokinetic (PK) characteristics of BH002 injection in Chinese patients with advanced solid tumors


Description:

Subjects will be administered BH002 intravenously. It is expected that there will be 2 to 4 dose groups, with 3 to 6 subjects enrolled in each group. The doses from low to high are 15 mg/m2,20 mg/m2,25 mg/m2,30 mg/m2,35 mg/m2. Subjects were injected with BH002 intravenously on the first day of each cycle, once during a 3-week period. The dose escalation for this trial will be 20mg/m2 as the starting dose. According to the traditional "3+3" dose escalation principle, 3 subjects are planned to be enrolled in each dose group at the same time. Safety, tolerability, and dose-limiting toxicities (DLTs) will be assessed within 21 days of first dose.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date March 31, 2023
Est. primary completion date March 10, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years old, male or female. 2. Patients were diagnosed advanced solid tumors by histology or cytology (preferably prostate cancer, gastric cancer, non-small cell lung cancer, breast cancer, esophageal cancer, head and neck squamous cell carcinoma, ovarian cancer, liposarcoma, etc.) whose disease progresses after standard treatment. 3. ECOG score 0~2, expected survival time =3 months. 4. Have adequate hematology and organ function, and meet the following conditions based on laboratory test results within 7 days before the first dose:1)For those who have not received blood transfusions, blood products or blood cytokines such as granulocyte colony-stimulating factor (G-CSF) within 14 days of the first dose, blood routine: neutrophil count =2.0×109/L, platelet count =100×109 /L, white blood cell count =4.0×109/L, hemoglobin concentration =8.0g/dL. 2)Blood biochemistry: liver function: aspartate aminotransferase and alanine aminotransferase =1.5 times the upper limit of normal (ULN), total bilirubin =ULN. kidney function: creatinine =1.5×ULN. 5. Baseline left ventricular ejection fraction determined by echocardiography =50%, normal or abnormal 12-lead electrocardiogram without clinical significance, QTc interval <450ms (men) or <470ms (women), and no symptoms or signs of heart failure. 6. The functions of major organs (heart, lung, liver, kidney, bone marrow, gastrointestinal) are basically normal or abnormal without clinical significance, and acute toxicity caused by previous treatment is relieved to = grade 1 (except for hair loss). 7. If the subject has been previously treated with surgery, chemotherapy, immunotherapy, biologic therapy, targeted therapy, anti-tumor traditional Chinese medicine, or small molecule targeted drug, the first dose should be given at an interval of 4 weeks or more than 5 half-lives (whichever is shorter);If the chemotherapeutic agent is mitomycin or nitrosourea, the first dose needs to be given more than 6 weeks apart. 8. The first dose was more than 6 weeks after the last radiotherapy (except palliative radiotherapy for local pain control), and there was no previous whole-pelvic radiotherapy (radiotherapy =30% of the bone marrow area). 9. With the consent of the individual and an informed consent form signed by the individual or his legal representative. 10. The subject can communicate well with the researcher and complete the research in accordance with the research regulations. Exclusion criteria: 1. Those who have received cabazitaxel in the past. 2. Those who are severely allergic to cabazitaxel, human albumin, or alcohol. 3. Currently receiving other anti-tumor therapys. 4. Patients receiving systemic therapy with glucocorticoids (>10 mg/d prednisone or equivalent dose of steroids) or other immunosuppressants within 14 days before the first dose. In the absence of active autoimmune disease, inhaled or topical glucocorticoids can be used, and hormone replacement therapy doses =10 mg/d prednisone equivalent are allowed. 5. Those who need to use strong inhibitors or inducers of CYP3A4 within 14 days of the first dose and during the study. 6. Those with clinically significant mental or central nervous system diseases. 7. Those with active brain metastasis. 8. Those with two or more malignant tumors (except cured non-melanoma skin cancer, cervical cancer, thyroid cancer and gastrointestinal intramucosal cancer) 9. Subjects who have received 2 or more prior treatments with mitomycin or nitrosoureas, or subjects who have received prior intensive therapy with autologous stem cell transplantation. 10. Those with serious medical diseases:1)Existence of clinically important cardiovascular and cerebrovascular diseases, including: severe or uncontrollable heart disease that requires treatment, congestive heart failure rated = grade 3 by the New York Heart Association (NYHA), and unstable angina that cannot be controlled by drugs. A history of myocardial infarction within 6 months before enrollment, and severe arrhythmia requiring drug treatment (except for atrial fibrillation or paroxysmal supraventricular tachycardia). 2)Those with indwelling cardiac stent within 6 months.3)Uncontrolled hypertension (systolic blood pressure =160mmHg and/or diastolic blood pressure =100mmHg), diabetes, pleural effusion, pericardial effusion, and ascites. 4)Uncontrolled peptic ulcer, or other uncontrolled thromboembolic event. 5)Patients with interstitial lung disease, pulmonary fibrosis, or a history of pneumonia who require steroid treatment. 11. People who are infected with HIV, HBV [those who are positive for hepatitis B surface antigen (HBsAg) and whose HBV-DNA is higher than 1000IU/mL], HCV ( those who are HCV-Ab positive and whose HCVRNA detection copy number is higher than normal upper limit)and Treponema pallidum. 12. Those with a history of drug abuse. 13. Women who are pregnant or lactating. female patients of childbearing potential who have a positive pregnancy test within 7 days before the first dose. any male and female patients of childbearing potential do not consent to the use of a medically recognized effective method of contraception throughout the trial and for 3 months after final trial drug administration. 14. Those who have participated in other drug clinical trials within 28 days before the first dose. 15. Those who have been vaccinated within 30 days before the first dose or vaccinated during the study period (except for inactivated vaccines). 16. Other circumstances in which the researcher deems it inappropriate to participate in this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BH002
Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle

Locations

Country Name City State
China Hunan Cancer Hospital Changsha Hunan
China Fudan University Shanghai Cancer Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Zhuhai Beihai Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluating the tolerability of BH002 in Chinese patients with advanced solid tumors. dose-limiting toxicity [DLT] 21 days after first dose
Primary Evaluating the tolerability of BH002 in Chinese patients with advanced solid tumors. maximum tolerated dose [MTD] 21 days after first dose
Primary Obtain the pharmacokinetic characteristics of BH002 in Chinese patients with advanced solid tumors. Maximum Plasma Concentration [Cmax], etc, 216 hours after first dose
Secondary To evaluate the safety of BH002 in Chinese patients with advanced solid tumors. Rates and severity of adverse events. From first dose to 30 days after last dose
Secondary Evaluating the preliminary anti-tumor activity of BH002 in Chinese patients with advanced solid tumors Preliminary observation of the therapeutic effect of the drug. From first dose to 30 days after last dose
Secondary Determination of recommended phase ? dose (RP2D) Explore clinically applicable doses and dosage regimens in the next phase. 21 days after first dose
See also
  Status Clinical Trial Phase
Completed NCT03315091 - Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours Phase 1
Completed NCT01921140 - To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours Phase 1
Completed NCT00732420 - Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors Phase 1
Recruiting NCT03572192 - Tissue Collection Framework To Improve Outcomes In Solid Tumours
Completed NCT02360345 - Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly Phase 1
Completed NCT02264418 - Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours Phase 1
Completed NCT02093351 - To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer Phase 1
Completed NCT01956669 - Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Phase 2
Recruiting NCT02215850 - Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours Phase 1
Recruiting NCT02263950 - A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT01900028 - To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours Phase 1
Completed NCT01931761 - Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers Phase 1
Completed NCT00136578 - Ispinesib In Combination With Carboplatin In Patients With Solid Tumors Phase 1
Completed NCT01184274 - A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia Phase 1
Withdrawn NCT03266159 - A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors Phase 2
Active, not recruiting NCT01894256 - Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function Phase 1
Completed NCT01974349 - To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Phase 1
Completed NCT02923947 - Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment Phase 1
Completed NCT02056392 - To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers Phase 1
Completed NCT02063204 - To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects Phase 1